The FDA on March 10, 2021 approved FOTIVDA®, a kinase inhibitor, for adult patients with Relapsed or Refractory advanced Renal Cell Carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® is a product of AVEO Pharmaceuticals, Inc.
Bottom Ad
Advertisement
Subscribe
